Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance as First-Line Treatment for Advanced Soft Tissue Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial
Clin. Cancer Res 2022 Oct 13;[EPub Ahead of Print], ZM Wang, RY Zhuang, X Guo, CL Zhang, Y You, LS Chen, WS Liu, Y Zhang, RK Luo, YY Hou, WQ Lu, YH ZhouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.